Cargando…
Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery
Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen Mycobacterium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods...
Autores principales: | Molloy, Antonia, Harrison, James, McGrath, John S., Owen, Zachary, Smith, Clive, Liu, Xin, Li, Xin, Cox, Jonathan A. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618277/ https://www.ncbi.nlm.nih.gov/pubmed/34835455 http://dx.doi.org/10.3390/microorganisms9112330 |
Ejemplares similares
-
Microfluidic-Based Multi-Organ Platforms for Drug Discovery
por: Rezaei Kolahchi, Ahmad, et al.
Publicado: (2016) -
Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery
por: Fu, Jingyu, et al.
Publicado: (2023) -
Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection
por: Shleider Carnero Canales, Christian, et al.
Publicado: (2023) -
Application of microfluidic technologies on COVID-19 diagnosis and drug discovery
por: Lin, Zhun, et al.
Publicado: (2023) -
EUS-guided liver biopsy: the optimal technique?
por: Wilen, Jonathan, et al.
Publicado: (2023)